HC Wainwright assumed coverage on shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $7.00 price objective on the biotechnology company’s stock.

A number of other research firms also recently weighed in on TRIL. Zacks Investment Research upgraded Trillium Therapeutics from a sell rating to a hold rating in a research report on Thursday, April 6th. Ladenburg Thalmann Financial Services reiterated a buy rating and issued a $18.00 price objective on shares of Trillium Therapeutics in a report on Friday, June 9th. Finally, Cowen and Company reiterated a buy rating on shares of Trillium Therapeutics in a report on Wednesday, July 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Trillium Therapeutics presently has a consensus rating of Buy and an average target price of $14.95.

Trillium Therapeutics (NASDAQ:TRIL) opened at 4.85 on Monday. Trillium Therapeutics has a 52 week low of $4.15 and a 52 week high of $17.70. The company’s market cap is $38.05 million. The company’s 50-day moving average price is $4.64 and its 200 day moving average price is $5.59.

TRADEMARK VIOLATION NOTICE: “Trillium Therapeutics Inc. (TRIL) Coverage Initiated at HC Wainwright” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/trillium-therapeutics-inc-tril-coverage-initiated-at-hc-wainwright/1454195.html.

A number of large investors have recently added to or reduced their stakes in the stock. Creative Planning increased its stake in Trillium Therapeutics by 1.1% in the second quarter. Creative Planning now owns 26,400 shares of the biotechnology company’s stock worth $116,000 after buying an additional 300 shares in the last quarter. Wells Fargo & Company MN increased its stake in Trillium Therapeutics by 34.1% in the first quarter. Wells Fargo & Company MN now owns 17,700 shares of the biotechnology company’s stock worth $109,000 after buying an additional 4,500 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in Trillium Therapeutics by 40.0% in the first quarter. Victory Capital Management Inc. now owns 77,601 shares of the biotechnology company’s stock worth $479,000 after buying an additional 22,171 shares in the last quarter. Institutional investors and hedge funds own 31.67% of the company’s stock.

Analyst Recommendations for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.